Claire Mazumdar, a biotech entrepreneur and CEO of a Nasdaq-listed firm based in the US, has been named as the future successor to Kiran Mazumdar-Shaw at Biocon. Kiran Mazumdar-Shaw, the founder and chairperson of Biocon, has officially laid out a succession plan, designating her niece Claire to eventually lead the company. She emphasized the importance of entrusting the business to capable hands, highlighting Claire’s proven leadership and management skills.
The transition of leadership, however, will not be immediate, as clarified by Mazumdar-Shaw. She mentioned in a social media post that she has no immediate plans to step down and that Claire will gradually assume the leadership role over time. Claire Mazumdar, aged 37, currently serves as the CEO of Bicara Therapeutics, a Boston-based biotechnology firm specializing in anti-cancer therapies.
With a strong academic background in both science and business, Claire holds degrees from prestigious institutions like the Massachusetts Institute of Technology and Stanford Graduate School of Business. Before her role at Bicara, she held positions at Third Rock Ventures and contributed to business development and corporate strategy at Rheos Medicines. Additionally, Claire is actively engaged in the non-profit sector, serving as a board member of Noora Health, an organization dedicated to enhancing healthcare outcomes through education for patients and caregivers.
Claire will receive support from a family-led leadership network, which includes her brother Eric Mazumdar, an expert in artificial intelligence and a professor at the California Institute of Technology, and her husband Thomas Roberts, a renowned oncologist at Massachusetts General Hospital in the US.
